Evidence map›Paper›PMID 41732217›Full record

ArticleThe Lancet regional health. Western Pacific2026

Vonoprazan-amoxicillin dual, rifabutin-based triple, and bismuth quadruple therapies for

Yu Huang, Jin-Nan Chen, Shu-Han Qiu, Yi-Xian Guo, Mei-Xuan Li, Ya-Nan Gao, Xiao Liang, Yue-Hua Han, Ping Xu, Jing Wang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Lancet regional health. Western Pacific, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Mechanism-matchedFrontiers in medicine · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yu HuangDivision of Gastroenterology and Hepatology, Shanghai Institute of Digestive Disease, NHC Key Laboratory of Digestive Diseases, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jin-Nan ChenDivision of Gastroenterology and Hepatology, Shanghai Institute of Digestive Disease, NHC Key Laboratory of Digestive Diseases, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Shu-Han QiuDivision of Gastroenterology and Hepatology, Shanghai Institute of Digestive Disease, NHC Key Laboratory of Digestive Diseases, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yi-Xian GuoDivision of Gastroenterology and Hepatology, Shanghai Institute of Digestive Disease, NHC Key Laboratory of Digestive Diseases, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Mei-Xuan LiDivision of Gastroenterology and Hepatology, Shanghai Institute of Digestive Disease, NHC Key Laboratory of Digestive Diseases, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Ya-Nan GaoDivision of Gastroenterology and Hepatology, Shanghai Institute of Digestive Disease, NHC Key Laboratory of Digestive Diseases, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Xiao LiangDivision of Gastroenterology and Hepatology, Shanghai Institute of Digestive Disease, NHC Key Laboratory of Digestive Diseases, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yue-Hua HanDepartment of Gastroenterology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Ping XuDepartment of Gastroenterology, Songjiang Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jing WangDepartment of Gastroenterology, Songjiang Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Hong LuDivision of Gastroenterology and Hepatology, Shanghai Institute of Digestive Disease, NHC Key Laboratory of Digestive Diseases, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Whether vonoprazan-amoxicillin dual therapy (VA) or rifabutin-based triple study (VRA) can replace bismuth quadruple therapy (BQT) for Methods: We conducted an open-label, non-inferiority randomised controlled trial at three hospitals in China. Refractory Findings: Between May 16, 2023, and Jan 31, 2025, 360 subjects (110 [31%] male and 250 [69%] female; mean age 48.4 years [SD 12.1]) were randomly assigned to VA, VRA or BQT (n = 120 per group). Intention-to-treat eradication rates were 75.8% (91/120; 95% CI 67.0-83.0) with VA, 90.0% (108/120; 95% CI 82.8-94.5) with VRA, and 90.8% (109/120; 95% CI 83.8-95.1) with BQT. Non-inferiority of VA to BQT was not established (difference -15.0%; 95% CI -24.2 to -5.8; p = 0.86), whereas VRA was non-inferior to BQT (difference -0.8%; 95% CI -8.3 to 6.6; p = 0.0078). Resistance rates for amoxicillin, rifabutin, tetracycline, and metronidazole were 10%, <1%, 0.0%, and 96%, respectively. Amoxicillin resistance, BMI ≥25 kg/m Interpretation: Ten-day VRA therapy is a viable alternative to BQT therapy for Funding: National Natural Science Foundation of China, and Xinyi Digestive Disease Fund Project, College of Digestive Sciences, Shanghai Jiao Tong University School of Medicine.

Indexed as

AmoxicillinBismuth quadruple therapyHelicobacter pyloriRescue therapyRifabutin

Identifiers

PMID41732217
PMCPMC12925073

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.